Investigating the spatial and temporal regulation of NKX2.5+ alpm progenitors in outflow tract development
Active Project Grant Awarded Last action
- Award ID
- F32HL186603
- Recipient
-
The Children's Hospital Corporation UEI Z1L9F1MM1RY3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $82,348
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 0% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
Description
- Abstract
- Conotruncal defects are among the most severe and life-threatening forms of congenital heart disease (CHD), including conditions like tetralogy of fallot and double outlet right ventricle. Notably, anomalies in the formation or remodeling of the outflow tract (OFT), located within the conotruncus, are often associated with genetic syndromes such as 22Q11 deletion syndrome. The OFT develops from a subset of multipotent cells in the anterior lateral plate mesoderm (ALPM), known as the second heart field (SHF), which expresses the cardiac transcription factor NKX2.5. Recently, we discovered that the heterogeneous NKX2.5+ ALPM is spatially and transcriptionally organized based on their specific cardiopharyngeal fates earlier in development than previously believed. However, the mechanisms orchestrating the migration and differentiation of OFT-fated progenitors from this heterogeneous pool into their respective final cell lineages remain unknown. In this study, we aim to (1) create a spatiotemporal map of NKX2.5+ progenitor development and (2) identify the gene regulatory networks that govern their migration and differentiation to the OFT. To address these aims, I will use the zebrafish model system, which offers unparalleled capabilities for tracking and analyzing progenitor cells throughout their external embryonic development. I will employ an integrated approach that includes kaede-mediated photoconversion, whole-mount immunofluorescence, and in situ hybridization to determine when and where OFT-fated progenitors differentiate. Additionally, I will combine innovative spatial transcriptomics with loss-of-function studies to uncover the mechanistic signals that drive progenitor migration and differentiation within their pharyngeal microenvironment. Ultimately, understanding the developmental pathways and mechanisms underlying OFT formation will enhance our knowledge of CHD etiology. This work will be carried out in the ideal environment provided by the department of cardiology at boston children's hospital, under the mentorship of cardiovascular development expert DR. Caroline burns and bioinformatician expert DR. Kaifu chen. Additional support from my scientific advisory committee, along with resources from harvard medical school, will ensure the success of the proposed research and my growth as an independent scientist.
Quick answers
Who received award F32HL186603?
F32HL186603 was awarded to The Children's Hospital Corporation by National Heart Lung and Blood Institute (National Institutes of Health) on December 28, 2026.
How much is award F32HL186603 worth?
$82,348 has been obligated on F32HL186603.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award